Margaret A. Hamburg, M.D., Mandy Cohen, M.D., M.P.H., Karen DeSalvo, M.D., M.P.H., Julie Gerberding, M.D., M.P.H., Joneigh Khaldun, M.D., M.P.H., David Lakey, M.D., Ellen MacKenzie, Ph.D., Sc.M., Herminia Palacio, M.D., M.P.H., and Nirav R. Shah, M.D., M.P.H.
doi : 10.1056/NEJMp2207374
Vol. 387 No. 5
Whitney Arey, Ph.D., Klaira Lerma, M.P.H., Anitra Beasley, M.D., M.P.H., Lorie Harper, M.D., M.S.C.I., Ghazaleh Moayedi, D.O., M.P.H., and Kari White, Ph.D., M.P.H.
doi : 10.1056/NEJMp2207423
Zita Lazzarini, J.D., M.P.H.
doi : 10.1056/NEJMp2206055
Richard L. Wu, M.D., Azza H. Idris, M.D., Ph.D., Nina M. Berkowitz, M.P.H., Myra Happe, Ph.D., Martin R. Gaudinski, M.D., Christian Buettner, Ph.D., Larisa Strom, M.P.H., Seemal F. Awan, M.D., LaSonji A. Holman, F.N.P., Floreliz Mendoza, R.N., Ingelise J. Gordon, R.N., Zonghui Hu, Ph.D.,
doi : 10.1056/NEJMoa2203067
New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed.
Anthony E. Lang, M.D., Andrew D. Siderowf, M.D., Eric A. Macklin, Ph.D., Werner Poewe, M.D., David J. Brooks, M.D., D.Sc., Hubert H. Fernandez, M.D., Olivier Rascol, M.D., Nir Giladi, M.D., Fabrizio Stocchi, M.D., Caroline M. Tanner, M.D., Ph.D., Ronald B. Postuma, M.D., David K. Simon, M.D., Ph.D.,
doi : 10.1056/NEJMoa2203395
Aggregated α-synuclein plays an important role in Parkinson’s disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson’s disease.
Gennaro Pagano, M.D., Ph.D., Kirsten I. Taylor, Ph.D., Judith Anzures-Cabrera, Ph.D., Maddalena Marchesi, M.D., Tanya Simuni, M.D., Kenneth Marek, M.D., Ph.D., Ronald B. Postuma, M.D., Nicola Pavese, M.D., Ph.D., Fabrizio Stocchi, M.D., Ph.D., Jean-Philippe Azulay, Ph.D., Brit Mollenhauer, M.D., Lydia López-Manzanares, M.D.,
doi : 10.1056/NEJMoa2202867
Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson’s disease.
Silva A. Arslanian, M.D., Tamara Hannon, M.D., Philip Zeitler, M.D., Ph.D., Lily C. Chao, M.D., Claudia Boucher-Berry, M.D., Margarita Barrientos-Pérez, M.D., Elise Bismuth, M.D., Sergio Dib, M.D., Ph.D., Jang Ik Cho, Ph.D., and David Cox, Ph.D. for the AWARD-PEDS Investigators*
doi : 10.1056/NEJMoa2204601
The incidence of type 2 diabetes mellitus is increasing among youths. Once-weekly treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist, may have efficacy with regard to glycemic control in youths with type 2 diabetes.
Kosuke Ishizuka, M.D., and Makoto Sugaya, M.D., Ph.D.
doi : 10.1056/NEJMicm2119475
Akbarshakh Akhmerov, M.D., and Danny Ramzy, M.D., Ph.D.
doi : 10.1056/NEJMicm2117229
Hannah X. Chen, M.D., Ph.D., Manuela Cernadas, M.D., Sara O. Vargas, M.D., Bruce D. Levy, M.D., and Joseph Loscalzo, M.D.
doi : 10.1056/NEJMcps2203306
Johanna P. Daily, M.D.
doi : 10.1056/NEJMe2207865
Timothy Wells, Sc.D., and Cristina Donini, Pharm.D., Ph.D.
doi : 10.1056/NEJMe2208131
Alan Whone, F.R.C.P., Ph.D.
doi : 10.1056/NEJMe2207681
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2210394
doi : 10.1056/NEJMc2207519
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟